| Literature DB >> 36014953 |
Magdalena Mróz1, Marcin Czub1, Anna Brytek-Matera1.
Abstract
Irritable bowel syndrome (IBS), as a functional and psychosomatic disease, reduces the quality of life and increases the risk of developing mental disorders. Deregulation of the autonomic nervous system (ANS) is one of the main causes of the disease. The objective of the present study was to identify the studies in which measurements of heart rate variability (HRV) were performed before and after therapeutic intervention, and to evaluate the effectiveness of IBS therapy in terms of a reduction of IBS symptoms and changes in autonomic tone. A systematic review of the literature was carried out in accordance with PRISMA standards. Six databases were searched for articles published before 2022: PubMed®, MEDLINE®, EBSCO, Cochrane, Scopus, and Web of Science. Inclusion criteria were experimental design, diagnosis of IBS (medical and/or diagnosis in accordance with the Rome Criteria), non-pharmacological intervention, and HRV measurement before and after the intervention. The quality of the studies was assessed by JBI Critical appraisal. In total, 455 studies were identified, of which, sixwere included in the review. Expected changes in HRV (increase in parasympathetic activity) were observed in four of the six studies (interventions studied: ear acupressure, transcutaneous auricular vagusnerve stimulation, cognitive behavioral therapy with relaxation elements, yoga). In the same studies, therapeutic interventions significantly reduced the symptoms of IBS. The present review indicated that interventions under investigation improve the efficiency of the ANS and reduce the symptoms of IBS. It is advisable to include HRV measurements as a measure of the effectiveness of interventions in IBS therapy, and to assess autonomic changes as a moderator of the effectiveness of IBS therapy.Entities:
Keywords: complementary therapies; heart rate variability; irritable bowel syndrome; mind-body therapies
Mesh:
Year: 2022 PMID: 36014953 PMCID: PMC9416471 DOI: 10.3390/nu14163447
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Schema the relationship between disturbed autonomic balance and IBS symptoms. Note: Permanent stress and negative emotions inhibit the vagus nerve function, which manifests itself in hypoactivity of the PNS. Under the stress, the homeostasis of the intestinal epithelium is disturbed, and the microbiota composition is modified, e.g., reduction of fecal microbial diversity, which may lead to dysbiosis. Impaired secretory and barrier functions of the intestinal mucosa are characterized by increased intestinal permeability and secretion, which contribute to the development of intestinal inflammation and disturbances in intestinal motility. Inflammation causes pain, problems with defecation (diarrhea/constipation), and the visceral hypersensitivity increases. These symptoms affect neurophysiological changes (including lowering the pain threshold) and mental changes (increased anxiety, depression) in the brain, which secondarily generates stress and reduces the anti-inflammatory efficiency of the vagus nerve. This simplified elaboration is based on Bonaz et al., 2018 [11] and Drossman, 2016 [1].
Figure 2Flow diagram for systematic review.
General characteristics of research studies included in the review.
| Author | Year | Country | N (E/C) | % Women | Rome Criteria | IBS Type | Methods for Assessing IBS Symptoms | Methods for Assessing Secondary Outcomes |
|---|---|---|---|---|---|---|---|---|
| Jang et al. [ | 2017 | Korea | 21/17 | 100 | III | IBS-C | GI Symptom Rating Scale (GSRS-IBS) | Anxiety, Depression: HADS; |
| Jurek et al. [ | 2021 | USA | 7/6 | 69.2 | n/d | n/d | IBS Severity Scoring System (IBS-SSS) | none |
| Kavuri, Selvan, Malamud et al. [ | 2015 | USA | 25/26/27 | 83.3 | III | IBS-C/D/M | IBS Severity Scoring System (IBS-SSS) | Anxiety, Depression: HADS |
| Park and Cha [ | 2012 | Korea | 21/21 | 100 | III | n/d | IBS module from Rome III Questionnaire (10 items); Bowel Symptom Severity Scale (BSSS) | Stress: GARS; |
| Go and Park [ | 2019 | South Korea | 29/27 | 100 | III | IBS-C/D/M | Bowel Symptom Severity Scale (BSSS) | Stress: PSS; |
| Shi et al. [ | 2021 | China | 21/19 | 75 | IV | IBS-C | IBS-SSS, Bristol stool form scale (BSFS), the bowel diary with Visual Analogue Scale (VAS) for abdominal pain | Anxiety/Depression: SAS/SDS |
C = control group; E = experimental group; GARS = Global Assessment of Recent Stress; HADS = Hospital Anxiety and Depression Scale; IBS-C = IBS with predominant constipation; IBS-D = IBS with predominant diarrhea; IBS-M = IBS with mixed bowel habits; n/d = no data; PSS = Perceived Stress Scale; SAS/SDS = the ZungSelf-rating Anxiety and Depression Scale; SCL-90R-K = Symptom Checklist–90–Revision, Korean version.
Characteristics of the experimental interventions used to treat IBS symptoms.
| Study | Intervention (E/C) | Duration/Frequency/ | Description |
|---|---|---|---|
| Jang et al. [ | CBT/general information about IBS | E: 8 weeks/once a week/ | E: Group session of CBT (4–6 participants) with 60 min of thematic training and 20 min of relaxation training. C: One session with 50 min of general information about IBS (during the first week). Similarly to the experimental group—an interview on IBS symptoms in groups of 4–6 people (four times: at baseline; and at 8, 16, and 24 weeks). |
| Jurek et al. [ | Slow deep breathing/normal activities | E: 4 weeks/5 times a week/20-min; C: normal activities | E: Self-directed Slow Deep Breathing with 20-min video. At least 4 times a week. C: maintenance regular activity. |
| Kavuri, Selvan, Malamud et al. [ | Yoga/Combination/ | Y/CB—Yoga RYM: 12 weeks/ | E: Each yoga session started with simple breathing practices, loosening practices, and simple postures with relaxation in between. The session ended with regulated breathing and meditation. C: maintenance of their regular activities; suggestion to walk for 60 min three times a week during their waiting period. |
| Park and Cha [ | KHA/sham-KHA | 4 weeks/twice a week/25 min | E: 16 KHA reflection spots on both hands were stimulated. The needles were inserted at less than 1 mm depth. C: 16 spots that were unrelated to the crucial energy spots were inserted by the needles. Each reflection spot wasstimulated for 25 min in both groups. |
| Go and Park [ | Auricular Acupressure/ | 4 weeks/5 days a week/5 times a day | E: Semen sinapis albae seeds were used to acupressure four auricular points: endocrine, large intestine, lung, and Shenmen. Stickers remained in place for 5 days, and sticker-attached areas were pressed 5 times a day. Acupressure stickers were applied weekly for 4 weeks with a 2-day break time between each treatment. C: No treatment. |
| Shi et al. [ | taVNS/ | 4 weeks/twice a day/30 min | E: “The taVNS treatment was performed at auricular cymba concha. One pair of electrodes was placed at bilateral auricular concha, via which trains of pulses were delivered from a watch-size digital stimulator” [ |
C = control group; CBT = cognitive behavioral therapy; E = experimental group; KHA = Korean hand acupuncture; RYM = remedial yoga module; taVNS = transcutaneous auricular vagusnerve stimulation; a Two experimental groups: (Y) yoga with limited conventional treatment, and (CB) yoga with conventional treatment; one control group: wait-list.
Methodology of HRV measurement.
| Study | Position and Length of Recordings | Time of HRV Recording | Frequency Ranges (Hz) | HRV Hardware | HRV Software | HRV Indicators |
|---|---|---|---|---|---|---|
| Jang et al. [ | seated, 10 min | unclear | HF: 0.15–0.4 | QECG-3 monitoring system (Laxtha Inc., Daejeon, Korea) | TeleScan Ver.2.8; Laxtha Inc. | HF, LF/HF |
| Jurek et al. [ | unclear | unclear | unclear | Polar heart rate monitor (Kempele, Finland) | Elite HRV app and Kubios software (Finland) | HF, LF/HF, PNS index, SNS index |
| Kavuri, Selvan, Malamud et al. [ | lying, 5 min | unclear | unclear | ECG and respiration—Biopac MP 45 Data Acquisition System (BIOPAC, CA, USA) | Kubios (version 2.2, Finland) | HF, LF, LF/HF |
| Park & Cha [ | seated, 5 min | unclear | unclear | SA-3000P (Medicore Co. Ltd., Seoul, Korea) | SDRR, PSI, TP, VLF, LF, HF, LF-Norm, HF-Norm, LF/HF | |
| Go & Park [ | seated, twice a for 5 min | unclear | unclear | SA-3000P (Medicore Co. Ltd., Seoul, Korea) | SDRR, PSI, TP, LF-Norm, HF-Norm, LF/HF | |
| Shi et al. [ | lying, 30 min | unclear | HF: 0.15–0.50 | ECG-01A (Ningbo Maida Medical Device Inc., Ningbo, China) | unclear | LF-Norm, HF-Norm |
ECG = electrocardiogram; HF = high frequency; HF-norm = normalized high frequency (HF/LF + HF); LF = low frequency; LF/HF = low frequency/high frequency ratio; LF-norm = normalized low frequency (LF/LF + HF); PNS index = parasympathetic nervous system index; PSI = physical stress index; SDRR = standard deviation of RR intervals; SNS index = sympathetic nervous system index; TP = total power; VLF = very low frequency; a average for analysis.
Results and conclusions of the studies included in the review. Comparison of the size of effects for primary and secondary variables.
| Primary and Secondary Variables | Methods for Assessing Variables | Effect Sizes a | Significance Level | Conclusions |
|---|---|---|---|---|
| IBS symptoms | IBS-SSS | d = 1.30 | taVNS improved HRV parameters—increased the vagal activity (HF-norm). taVNS reduced IBS symptoms, pain, anxiety, and depression, and improved quality of life. | |
| HRV | HF-norm | d = −0.66 | ||
| LF-norm | n/d | n/d | ||
| Pain | VAS | d = 1.17 | ||
| Anxiety | SAS | d = 1.24 | ||
| Depression | SDS | d = 0.84 | ||
| Stress | not measured | |||
| IBS symptoms | BSSS-AD-F | d = 0.81 | n/d | Auricular acupressure effectively reduced IBS symptoms. The severity of loose stools, diarrhea, abdominal pain, and abdominal discomfort were lower. |
| BSSS-AD-DS. | d = 1.16 | n/d | ||
| BSSS-AD-DB | d = 1.52 | n/d | ||
| HRV | HF-norm | d = −1.1 | n/d | |
| LF-norm | d = 0.88 | n/d | ||
| LF/HF | d = 0.88 | n/d | ||
| PSI | d = 0.29 | n/d | ||
| SDRR | d = −0.59 | n/d | ||
| Pain | BSSS-AP-F | d = 0.42 | n/d | |
| BSSS-AP-DS. | d = −0.70 | n/d | ||
| BSSS-AP-DB | d = 0.97 | n/d | ||
| Anxiety | SCL-90R-K-A | d = 0.24 | n/d | |
| Depression | SCL-90R-K-D | d = 0.13 | n/d | |
| Stress | PSS | d = 1.07 | n/d | |
| IBS symptoms | BSSS-AD-F | d = 0 | n/d | Some of the symptoms of IBS have improved—especially those related to abdominal pain: frequency of loose stools and abdominal pain, reduction of anxiety and perceived disability caused by abdominal pain, flatulence, and discomfort in the abdominal cavity. |
| BSSS-AD-DS. | d = −0.32 | n/d | ||
| BSSS-AD-DB | d = −0.24 | n/d | ||
| HRV | HF-norm | d = 0.18 | n/d | |
| HF | d = −0.39 | n/d | ||
| LF-norm | d = −0.18 | n/d | ||
| LF | d = −0.24 | n/d | ||
| LF/HF | d = −0.20 | n/d | ||
| PSI | d = 0.48 | n/d | ||
| SDRR | d = −0.42 | n/d | ||
| Pain | BSSS-AP-F | d = 0.19 | n/d | |
| BSSS-AP-DS. | d = 0.15 | n/d | ||
| BSSS-AP-DB | d = −0.32 | n/d | ||
| Anxiety | SCL-90R-K-A | d = −0.11 | n/d | |
| Depression | SCL-90R-K-D | d = −0.05 | n/d | |
| Stress | GARS | d = −0.51 | n/d | |
| IBS symptoms | IBS-SSS | d = −0.19 | n/d | There were no changes in the functioning of the autonomic system (no significant differences in HRV). |
| HRV | HF | d = 0 | n/d | |
| LF/HF | d = 0.16 eta2 = 0.47 | n/d | ||
| PNS index | d = 0.80 | n/d | ||
| SNS index | d = 0.18 | n/d | ||
| Pain | not measured | |||
| Anxiety | ||||
| Depression | ||||
| Stress | ||||
| IBS symptoms | GSRS-IBS | n/d | Significant changes in the functioning of ANS were observed—CBT resulted in a significant increase in HF and a significant decrease in the LF/HF ratio. These changes coexisted with significant reductions in IBS symptoms, anxiety, depression, and stress. Differences in HF and the LF/HF ratio were significantly associated with changes in symptoms of IBS, anxiety, depression, and stress. | |
| HRV | HF | n/d | ||
| LF/HF | n/d | |||
| Pain | not measured | |||
| Anxiety | HADS-A | n/d | ||
| Depression | HADS-D | n/d | ||
| Stress | GARS | n/d | ||
| IBS symptoms | IBS-SSS | Y vs. WL: d = 4.03 | The remedial yoga module (RYM) reduces symptoms of IBS, anxiety, and depression (in both groups: (Y), yoga with limited conventional treatment; and (CB), combination—yoga with conventional treatment). | |
| CB vs. WL: d = 3.12 | ||||
| Y vs. CB d = 0.52 | ||||
| HRV | HF | n/d | CB vs. WL: | |
| LF | n/d | CB vs. WL: | ||
| LF/HF | n/d | CB vs. WL: | ||
| Pain | not measured | |||
| Anxiety | HADS-A | n/d | Y vs. WL *** | |
| n/d | CB vs. WL *** | |||
| n/d | Y vs. CB | |||
| Depression | HADS-D | n/d | Y vs. WL *** | |
| n/d | CB vs. WL *** | |||
| n/d | Y vs. CB | |||
| Stress | not measured | |||
IBS-SSS, IBS Symptom Severity Scale; BSSS-AD, Bowel Symptom Severity Scale; AD, abdominal discomfort: F = frequency, DS = distress, DB = disability; AP = abdominal pain; GARS, Global Assessment of Recent Stress; GSRS-IBS, GI Symptom Rating Scale; HADS, Hospital Anxiety and Depression Scale; HF, high frequency; HF-norm, normalized high frequency (HF/LF + HF); HRV = heart rate variability; KHA, Korean hand acupuncture; LF, low frequency; LF/HF, low frequency/high frequency ratio; LF-norm, normalized low frequency LF (LF/LF + HF); n/d = no data; PNS index, parasympathetic nervous system index; PSI, physical stress index; PSS, Perceived Stress Scale; SAS, Self-rating Anxiety Scale; SCL-90R-K-A/D, Symptom Checklist–90–Revision, Korean version; A = anxiety, D = depression; SDRR, standard deviation of RR intervals; SDS, self-rating depression scale; SNS index, sympathetic nervous system index; taVNS, transcutaneous auricular vagus nerve stimulation; VAS, Visual Analogue Scale. a The effect sizes were calculated based on the mean differences between the groups in the post-test. d = Cohen’s d effect size (When the effect sizes were not available, they have been calculated from means and standard deviations.). *** = p < 0.001.
Results of JBI Critical Appraisal for Quasi-Experimental Studies.
| Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Overall a |
|---|---|---|---|---|---|---|---|---|---|---|
| Park & Cha [ | + | + | ? | + | + | − | + | ? | + | 6.00 |
| Go & Park [ | + | + | + | + | + | ? | + | ? | + | 7.00 |
| Jurek et al. [ | + | − | ? | + | + | ? | + | ? | + | 5.00 |
Note. +, criterion fulfilled; −, criterion not fulfilled; ?, unclear; a Interpretation: 0—high; 9—low risk of bias.
Results of JBI Critical Appraisal for Randomized Controlled Trials.
| Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Overall a |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jang et al. [ | + | ? | + | ? | - | + | − | ? | − | + | ? | + | + | 6.00 |
| Kavuri, Selvan, Malamud et al. [ | + | + | + | ? | + | + | − | ? | + | + | ? | + | + | 9.00 |
| Shi et al. [ | + | − | + | + | − | − | + | + | + | + | ? | + | + | 9.00 |
Note. +, criterion fulfilled; −, criterion not fulfilled; ?, unclear; a Interpretation: 0—high; 13—low risk of bias.